Lenalidomide in the treatment of young patients with multiple myeloma: From induction to consolidation/maintenance therapy

Barbara Lupo, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma is the second most common hematologic malignancy. It accounts for 20,580 new cancer cases in the USA in 2009, including 11,680 cases in men, 8,900 cases in women, and 10,580 deaths overall. Although the disease remains still incurable, outcomes have improved substantially over recent years thanks to the use of high-dose therapy and the availability of novel agents, such as the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. Various trials have shown the advantages linked to the use of novel agents in the transplant and not-transplant settings. In particular, this paper will present an overview of the results achieved with lenalidomide-containing combinations in patients eligible for high-dose therapies, namely, young patients. The advantages obtained should always be outweighed with the toxicity profile associated with the regimen used. Therefore, here, we will also provide a description of the main adverse events associated with lenalidomide and its combination.

Original languageEnglish
Article number906247
JournalAdvances in Hematology
Volume2012
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Lenalidomide in the treatment of young patients with multiple myeloma: From induction to consolidation/maintenance therapy'. Together they form a unique fingerprint.

Cite this